ストックスクリーナーアプリを入手
395.89
0.70%
-2.927
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
U.S. Transthyretin Amyloidosis Treatment Market Insights - openPR.com
Cardiovascular Biologics Market to Reach USD 4.23 Billion - openPR.com
Japan Gene Therapy Market is expected to reach US$ 904.94 Million - openPR.com
Alnylam plans $250M investment in Norton manufacturing facility, US - MSN
Highland Capital Management LLC Buys Shares of 4,569 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Massachusetts lands rare manufacturing wins from Moderna and Alnylam amid tariff push - The Business Journals
Brighton Jones LLC Acquires 3,909 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion - simplywall.st
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23) - ts2.tech
Here’s why Alnylam Pharmaceuticals (ALNY) surged in Q3 - MSN
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook - ts2.tech
Alnylam Pharmaceuticals, Inc.(NasdaqGS: ALNY) added to NASDAQ-100 Index - marketscreener.com
Alnylam Pharmaceuticals Earnings Notes - Trefis
RNAi (RNA Interference) Technology Market to Reach US$ 6.63 - openPR.com
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open - ts2.tech
Bear Alert: Why Alnylam Pharmaceuticals Inc. stock could be next big winnerQuarterly Risk Review & Low Risk Profit Maximizing Plans - Улправда
118,800 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Congress Asset Management Co. - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
PeptiDream (TSE:4587): Assessing Valuation After New IL-17 Oral Candidate and Alnylam siRNA Milestone - Yahoo Finance
Market Moves: Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterQuarterly Profit Review & AI Driven Price Forecasts - ulpravda.ru
Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025 - ts2.tech
Will Alnylam Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Performance Recap & Expert Curated Trade Ideas - ulpravda.ru
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by U.S. Capital Wealth Advisors LLC - MarketBeat
What PeptiDream (TSE:4587)'s New Oral IL-17 Program and RNAi Milestone Mean For Shareholders - Yahoo! Finance Canada
Is Alnylam Pharmaceuticals Inc. stock recession proofJuly 2025 Trends & AI Powered Market Entry Ideas - Улправда
Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open - ts2.tech
Portfolio Recap: Will Alnylam Pharmaceuticals Inc. stock remain a Wall Street favoriteJuly 2025 Trends & Accurate Entry and Exit Point Alerts - ulpravda.ru
Why Alnylam Pharmaceuticals Inc. stock remains undervaluedJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterChart Signals & Free Long-Term Investment Growth Plans - Улправда
Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q3 - Finviz
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive post correctionMarket Activity Report & Weekly Stock Breakout Alerts - DonanımHaber
Will Alnylam Pharmaceuticals Inc. stock attract more institutional investorsOil Prices & Verified Momentum Stock Watchlist - DonanımHaber
How buybacks impact Alnylam Pharmaceuticals Inc. stock valueJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - DonanımHaber
Here’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q3 - Insider Monkey
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Alnylam’s Manufacturing Expansion and Extra-Hepatic RNAi Delivery Could Be A Game Changer For Alnylam Pharmaceuticals (ALNY) - Yahoo Finance
Is It Too Late to Consider Alnylam After a 67.8% Surge in 2025? - Yahoo Finance
Alnylam Announces 250M Investment To Expand US Manufacturing Capacity In Massachusetts For RNAi Therapeutics - Bioprocess Online
Demand prompts Alnylam’s $250 million manufacturing expansion - The Pharma Letter
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues - BioSpace
Alnylam plans $250m investment in Norton manufacturing facility, US - Yahoo Finance
Alnylam to invest $250 million in expanding RNA drug manufacturing By Investing.com - Investing.com Nigeria
Alnylam launching $250 million biomanufacturing expansion in Norton - The Boston Globe
Alnylam's $250M Norton facility upgrade aims to slash need for 20 plants down to 2 - The Business Journals
Alnylam to Invest $250M in U.S. Manufacturing Expansion for RNAi Therapeutics - citybiz
Alnylam (ALNY) Advances Norton Facility with $250M Investment - GuruFocus
Alnylam Pharmaceuticals to Invest $250 Million on Enzymatic Ligation Manufacturing Platform - marketscreener.com
Alnylam to invest $250 million to add enzymatic ligation platform - marketscreener.com
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics - Business Wire
Sanders Morris Harris LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis - BioSpace
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - MSN
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Novan (NOVN) and Dyadic International (DYAI) - The Globe and Mail
Alnylam announces Health Canada approval of Amvuttra® - marketscreener.com
Alnylam Pharmaceuticals (ALNY) Stock Price, Quote, News & History - Benzinga
Gene Therapy Market to Reach US$ 35.91 Billion by 2033 at 23.1% - openPR.com
Is Alnylam Entering A Corrective Phase After A Strong Run? - Sahm
Assessing Alnylam Pharmaceuticals’ (ALNY) Valuation After Its Inclusion in the Nasdaq 100 Index - Yahoo Finance
0.10%
大文字化:
|
ボリューム (24 時間):